| Literature DB >> 25530969 |
Xian-Ming Chu1, Bing Li2, Yi An1, Xue-Bin Li3, Ji-Hong Guo3.
Abstract
Asymptomatic bacterial colonization of cardiovascular implantable electronic devices (CIEDs) is widespread and increases the risk of clinical CIED infection. The aim of the study was to evaluate the incidence of bacterial colonization of generator pockets in patients without signs of infection and to analyze the relationship with clinical infection and risk factors. From June 2011 to December 2012, 78 patients underwent CIED replacement or upgrade. Exclusion criteria included a clinical diagnosis of CIED infection, bacteremia, or infective endocarditis. All patients were examined for evidence of bacterial 16S rDNA on the device and in the surrounding tissues. Infection cases were recorded during follow-up. The bacterial-positive rate was 38.5% (30 cases); the coagulase-negative Staphylococcus detection rate was the highest (9 cases, 11.5%). Positive bacterial DNA results were obtained from pocket tissue in 23.1% of patients (18 cases), and bacterial DNA was detected on the device in 29.5% of patients (23 cases). During follow-up (median 24.6 months), two patients (6.7%, 2/30) became symptomatic with the same species of microorganism, S. aureus and S. epidermidis. Multivariable logistic regression analysis found that the history of bacterial infection, use of antibiotics, application of antiplatelet drugs, replacement frequency, and renal insufficiency were independent risk factors for asymptomatic bacterial colonization.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25530969 PMCID: PMC4233659 DOI: 10.1155/2014/725163
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1UP-PCR results of some patients. We have detected all the patients and finally we chose some positive bacteria and carried out the electrophoresis, so every line had PCR products. The deeper the stripe, the more the bacteria. Lines 1–9 represented PCR product of the 16S rRNA gene of Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Streptococcus viridans, Staphylococcus saprophyticus, Corynebacterium parvum, Klebsiella pneumoniae, and Enterobacter cloacae; M for DL2000 DNA Marker; ten for negative control.
Figure 2Identification of enzyme digestion of 16S rRNA gene recombinant. 1, 3: enzyme-digested product of 16S rRNA gene recombinant plasmid; 2, 4: blank pGEM-T plasmid; M for DL2000 DNA Marker.
Baseline characteristics of 78 patients.
| DNA positive | DNA negative | χ2 |
| |
|---|---|---|---|---|
| Age | 69.1 ± 15.2 | 67.8 ± 17.1 | 1.0838 | 0.2819 |
| Gender | 0.624 | 0.429 | ||
| Male | 17 | 23 | ||
| Female | 13 | 25 | ||
| PM indications | 0.707 | 0.702 | ||
| SSS | 14 | 20 | ||
| AVB | 10 | 21 | ||
| AF with long intervals | 6 | 7 | ||
| Replacement time | Fisher | 0.004 | ||
| 1 time | 22 | 46 | ||
| 2 times | 6 | 2 | ||
| 3 times | 2 | 0 | ||
| PM types | Fisher | 1.0 | ||
| Single chamber | 10 | 15 | ||
| Double chamber | 19 | 31 | ||
| ICD/CRT | 1 | 2 | ||
| Temporary PM application | 3 | 2 | Fisher | 0.381 |
PM, pacemaker; SSS, sick sinus syndrome; AVB, atrioventricular block; AF, atrial fibrillation with long intervals.
Physiological characteristics of 78 patients.
| DNA positive | DNA negative |
|
| |
|---|---|---|---|---|
| Body mass index | 25.22 ± 4.78 | 26.02 ± 4.02 | 0.7974 | 0.4277 |
| White blood cells (×109/L) | 6.23 ± 2.1 | 6.06 ± 2.2 | 0.34 | 0.7348 |
| Blood platelets (×109/L) | 230.24 ± 40.21 | 226.98 ± 35.78 | 0.3748 | 0.7088 |
| Hemoglobin (g/L) | 135.46 ± 8.94 | 136.59 ± 8.08 | 0.5793 | 0.5641 |
| Total serum protein (g/L) | 63.66 ± 6.58 | 64.28 ± 6.69 | 0.4031 | 0.688 |
| Serum albumin (g/L) | 42.64 ± 4.03 | 44.05 ± 4.12 | 1.4919 | 0.1399 |
| Ejection fraction (EF %) | 54.68 ± 8.76 | 56.69 ± 7.49 | 1.0838 | 0.2819 |
Comorbidities and drug application.
| DNA positive | DNA negative | χ2 |
| |
|---|---|---|---|---|
| Chronic heart disease | 12 | 14 | 0.669 | 0.413 |
| Coronary heart disease | 8 | 10 | 0.216 | 0.642 |
| Hypertension | 14 | 22 | 0.02 | 0.886 |
| Atrial fibrillation | Fisher | 0.631 | ||
| Paroxysmal | 6 | 5 | ||
| Persistent | 3 | 6 | ||
| Permanent | 3 | 5 | ||
| Dilated cardiomyopathy | 6 | 6 | Fisher | 0.526 |
| Diabetes | 7 | 8 | 0.372 | 0.542 |
| Renal insufficiency | 6 | 2 | Fisher | 0.053 |
| Chronic systolic HF | 6 | 11 | 0.672 | |
| COPD | 2 | 3 | Fisher | 1.0 |
| Immunosuppressor | 1 | 2 | Fisher | 1.0 |
| Warfarin | 1 | 2 | Fisher | 1.0 |
| Antiplatelet drug use | 20 | 15 | 8.026 | 0.005 |
| Antibiotic use | 11 | 3 | 10.741 | 0.001 |
| Malignancy | 1 | 1 | Fisher | 1.0 |
| Bacterial infection history | 29 | 11 | 36.787 | 0.0001 |
| Surgical history | 3 | 4 | Fisher | 1.0 |
HF, heart failure; COPD, chronic obstructive pulmonary disease.
Multifactor logistic regression analysis.
| Risk factor |
| SE ( | Wald |
| OR | 95% CI |
|---|---|---|---|---|---|---|
| Bacterial infection history | 3.596 | 0.793 | 21.79 | <0.0001 | 36.45 | 6.85–198.231 |
| Antibiotic use | 2.104 | 0.695 | 7.934 | 0.004 | 8.198 | 2.01–30.47 |
| Antiplatelet drug use | 1.324 | 0.474 | 7.362 | 0.005 | 3.758 | 1.287–9.645 |
| Replacement of two times | 1.732 | 0.818 | 4,126 | 0.031 | 5.65 | 1.131–30.82 |
| Renal insufficiency | 1.634 | 0.831 | 3.871 | 0.041 | 5.12 | 1.004–26.73 |
Replacement times: significant difference between 2 and 1 times, no difference between 3 and 1 times.
Bacterial species determined by DNA technology (n, %).
| Species | Positive number ( | Percentage (%) |
|---|---|---|
|
| 1 | 3.3 |
|
| 9 | 30.0 |
|
| 4 | 13.3 |
|
| 2 | 6.7 |
|
| 2 | 6.7 |
|
| 1 | 3.3 |
|
| 2 | 6.7 |
|
| 3 | 10.0 |
|
| 3 | 10.0 |
|
| 4 | 13.3 |
|
| 2 | 6.7 |
|
| 3 | 10.0 |
|
| 4 | 13.3 |
|
| 1 | 3.3 |
DNA results of 78 patients.
| Specimen | Positive number ( | Percentage (%) |
|---|---|---|
| Overall | 30 | 38.5 |
| Pocket tissue | 18 | 23.1 |
| Surface of device | 23 | 29.5 |
| Both specimens | 11 | 14.1 |